Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
Stephen Padilla, 5 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Early antiviral therapy better than later treatment in babies with hepatitis B

24 Oct 2019

Early initiation of antiviral therapy leads to the rapid clearance of hepatitis B surface antigen (HBsAg) for infantile-onset infections, a new study has found.

Researchers enrolled 29 hepatitis B virus-infected infants who had persistently elevated alanine aminotransferase and high viral loads. Of these, 18 underwent lamivudine antiviral therapy before 1 year of age (group 1; median age at treatment, 8 months), as decided by their parents, while the remaining 11 initiated interferon-α therapy after they had turned 1 year (group 2; median age at treatment, 12 months).

By 3, 6, 9 and 12 months after treatment initiation, group 1 showed cumulative HBsAg clearance rates of 39 percent, 67 percent, 78 percent and 83 percent, respectively. The corresponding values in group 2 were 18 percent, 27 percent, 27 percent and 36 percent. The between-group difference after 12 months of treatment was statistically significant (p=0.0169).

Moreover, in the ensuing follow-up period, two additional patients in group 1 achieved HBsAg loss compared with none in group 2.

Only one participant, who belonged to group 2, did not eventually achieve seroconversion and accordingly terminated antiviral treatment. Off-treatment follow-up lasted for a median of 102 months, during which time no relapse had been observed.

Both treatment regimens were reasonably safe, such that no serious adverse events were reported over the course of the study. The most common side effects were fever, neutropoenia, decreased appetite, febrile convulsion and rashes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
Stephen Padilla, 5 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).